These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

396 related articles for article (PubMed ID: 25816822)

  • 21. New trends and challenges in the European regulation of innovative medicines.
    Enzmann H
    Regul Toxicol Pharmacol; 2016 Oct; 80():314-20. PubMed ID: 27237379
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Health technology assessment of medical devices: a survey of non-European union agencies.
    Ciani O; Wilcher B; Blankart CR; Hatz M; Rupel VP; Erker RS; Varabyova Y; Taylor RS
    Int J Technol Assess Health Care; 2015 Jan; 31(3):154-65. PubMed ID: 26044729
    [TBL] [Abstract][Full Text] [Related]  

  • 23. EARLY DIALOGUE IN EUROPE: PERSPECTIVES ON VALUE, CHALLENGES, AND CONTINUING EVOLUTION.
    Balaisyte L; Joos A; Hiligsmann M
    Int J Technol Assess Health Care; 2018 Jan; 34(5):514-518. PubMed ID: 30246671
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparing Use of Health Technology Assessment in Pharmaceutical Policy among Earlier and More Recent Adopters in the European Union.
    Beletsi A; Koutrafouri V; Karampli E; Pavi E
    Value Health Reg Issues; 2018 Sep; 16():81-91. PubMed ID: 30316029
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Avoiding and identifying errors in health technology assessment models: qualitative study and methodological review.
    Chilcott J; Tappenden P; Rawdin A; Johnson M; Kaltenthaler E; Paisley S; Papaioannou D; Shippam A
    Health Technol Assess; 2010 May; 14(25):iii-iv, ix-xii, 1-107. PubMed ID: 20501062
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Harmonization of evidence requirements for health technology assessment in reimbursement decision making.
    Hutton J; Trueman P; Facey K
    Int J Technol Assess Health Care; 2008; 24(4):511-7. PubMed ID: 18828948
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Temporary authorization for use: does the French patient access programme for unlicensed medicines impact market access after formal licensing?
    Degrassat-Théas A; Paubel P; Parent de Curzon O; Le Pen C; Sinègre M
    Pharmacoeconomics; 2013 Apr; 31(4):335-43. PubMed ID: 23529210
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Health Technology Assessment in Japan: A Pharmaceutical Industry Perspective.
    Kido K; Matsumaru N; Tsukamoto K
    Ther Innov Regul Sci; 2019 Jul; 53(4):472-480. PubMed ID: 30157674
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Shedding light on the HTA consultancy market: Insights from Poland.
    Csanádi M; Ozierański P; Löblová O; King L; Kaló Z; Botz L
    Health Policy; 2019 Dec; 123(12):1237-1243. PubMed ID: 31466804
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relative effectiveness and the European pharmaceutical market.
    Jönsson B
    Eur J Health Econ; 2011 Apr; 12(2):97-102. PubMed ID: 21267624
    [No Abstract]   [Full Text] [Related]  

  • 31. The Development of the Romanian Scorecard HTA System.
    Radu CP; Chiriac ND; Pravat AM
    Value Health Reg Issues; 2016 Sep; 10():41-47. PubMed ID: 27881276
    [TBL] [Abstract][Full Text] [Related]  

  • 32. STAKEHOLDER INVOLVEMENT IN THE HEALTH TECHNOLOGY ASSESSMENT PROCESS IN LATIN AMERICA.
    Pichon-Riviere A; Soto N; Augustovski F; Sampietro-Colom L
    Int J Technol Assess Health Care; 2018 Jan; 34(3):248-253. PubMed ID: 29888698
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Development of archetypes for non-ranking classification and comparison of European National Health Technology Assessment systems.
    Allen N; Pichler F; Wang T; Patel S; Salek S
    Health Policy; 2013 Dec; 113(3):305-12. PubMed ID: 24176288
    [TBL] [Abstract][Full Text] [Related]  

  • 34. How aligned are the perspectives of EU regulators and HTA bodies? A comparative analysis of regulatory-HTA parallel scientific advice.
    Tafuri G; Pagnini M; Moseley J; Massari M; Petavy F; Behring A; Catalan A; Gajraj E; Hedberg N; Obach M; Osipenko L; Russo P; Van De Casteele M; Zebedin EM; Rasi G; Vamvakas S
    Br J Clin Pharmacol; 2016 Oct; 82(4):965-73. PubMed ID: 27245362
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early dialogue between the developers of new technologies and pricing and reimbursement agencies: a pilot study.
    Backhouse ME; Wonder M; Hornby E; Kilburg A; Drummond M; Mayer FK
    Value Health; 2011 Jun; 14(4):608-15. PubMed ID: 21669387
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The value and consequences of using public health technology assessments for private payer decision-making in Canada: one size does not fit all.
    Pericleous L; Amin M; Goeree R
    J Med Econ; 2019 May; 22(5):478-487. PubMed ID: 30757934
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan].
    Pflieger M; Bertram D
    Arch Pediatr; 2014 Oct; 21(10):1129-38. PubMed ID: 25175054
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CURRENT ENVIRONMENT FOR INTRODUCING HEALTH TECHNOLOGY ASSESSMENT IN GREECE.
    Kani C; Kourafalos V; Litsa P
    Int J Technol Assess Health Care; 2017 Jan; 33(3):396-401. PubMed ID: 28756795
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CHANGING HEALTH TECHNOLOGY ASSESSMENT PARADIGMS?
    Husereau D; Henshall C; Sampietro-Colom L; Thomas S
    Int J Technol Assess Health Care; 2016 Jan; 32(4):191-199. PubMed ID: 27766998
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The impact of parallel regulatory-health technology assessment scientific advice on clinical development. Assessing the uptake of regulatory and health technology assessment recommendations.
    Tafuri G; Lucas I; Estevão S; Moseley J; d'Andon A; Bruehl H; Gajraj E; Garcia S; Hedberg N; Massari M; Molina A; Obach M; Osipenko L; Petavy F; Petschulies M; Pontes C; Russo P; Schiel A; Van de Casteele M; Zebedin-Brandl EM; Rasi G; Vamvakas S
    Br J Clin Pharmacol; 2018 May; 84(5):1013-1019. PubMed ID: 29370449
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.